

Special Issue

Recent Developments in Proton Therapy of Head and Neck Cancer

Message from the Guest Editors

Head and neck cancer is a broad term, encompassing malignancies ranging from the paranasal sinuses, nasal cavity to the hypopharynx. Advancements in radiation technology, organ-preserving surgical techniques and the use of multimodality therapy have led to a paradigm shift in management, with the goal of toxicity reduction and possibly improved efficacy in select scenarios. Proton therapy is an emerging treatment modality for head and neck malignancies owing to its unique ability to spare critical organs in the head and neck using the Bragg-peak. This SI aims to highlight novel advancements in proton radiation that could improve long-term toxicity and outcomes in head and neck cancer management. The goal is to have a balanced view on proton therapy on the pros and cons for each disease subsite within the head and neck, reviewing the current evidence-based literature. In addition to the benefits of proton therapy, we will also address the complications associated with this technology and ongoing efforts to mitigate these toxicities.

Guest Editors

Dr. Nancy Lee

Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York City, NY 10065, USA

Dr. Irimi Youssef

Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Deadline for manuscript submissions

closed (30 July 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/200360

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)